As novel therapeutic approaches that inhibit EGFR more efficiently become widely implemented30, 31, 32, we speculate that the relative frequency of NSCLC to SCLC transformation in the setting of acquired resistance may increase moving forward, further underscoring the importance of understanding the basis for this transformation as well as treatment strategies to overcome it. The gene discussed is EGFR; the disease is small cell lung carcinoma.